The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
NCT03241199
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Chronic Myeloid Leukemia
Philadelphia Chromosome Positive CML
Interventions
DRUG:
Imatinib Mesylate
Sponsor
The University of Hong Kong